Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.
RECORD 3
RECORD 3 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled., Double-blind, Randomized Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.
2 other identifiers
interventional
2,531
19 countries
143
Brief Summary
The purpose of this study is to assess if 10 mg Bay 59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Feb 2006
Shorter than P25 for phase_3
143 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2006
CompletedFirst Submitted
Initial submission to the registry
August 8, 2006
CompletedFirst Posted
Study publicly available on registry
August 9, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2007
CompletedOctober 27, 2014
October 1, 2014
11 months
August 8, 2006
October 24, 2014
Conditions
Outcome Measures
Primary Outcomes (1)
Composite endpoint of total VTE i.e.: Any DVT (proximal and/or distal), Non fatal PE, Death of all causes
Treatment period: up to Day 13+/-4
Secondary Outcomes (8)
Incidence of the composite endpoint comprising proximal DVT, non-fatal PE and VTE- related death (major VTE)
Treatment period: up to Day 13+/-4
Incidence of symptomatic VTE (DVT, PE)
Treatment period: up to Day 13+/-4
Incidence of DVT (total, proximal, distal)
Treatment period: up to Day 13+/-4
Incidence of symptomatic VTE during follow-up
Follow-up period: following 13+/-4 days
The composite endpoint comprising major VTE and treatment-emergent major bleeding
For major VTE, treatment period: up to Day 13+/-4 ; for major bleeding, from first dose of double-blind study medication to up to two days after last dose of double-blind study medication
- +3 more secondary outcomes
Study Arms (2)
Arm 1
EXPERIMENTALArm 2
ACTIVE COMPARATORInterventions
10 mg rivaroxaban (tablet) once daily administered for 13 +/- 2 days
Eligibility Criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Bayerlead
Study Sites (143)
Unknown Facility
Graz, Styria, 8036, Austria
Unknown Facility
Innsbruck, Tyrol, 6020, Austria
Unknown Facility
Linz, Upper Austria, 4010, Austria
Unknown Facility
Vienna, Vienna, 1140, Austria
Unknown Facility
Antwerp, 2020, Belgium
Unknown Facility
Hasselt, 3500, Belgium
Unknown Facility
Liège, 4000, Belgium
Unknown Facility
Merksem, 2170, Belgium
Unknown Facility
Pellenberg, 3212, Belgium
Unknown Facility
Reet, 2840, Belgium
Unknown Facility
Roeselare, 8800, Belgium
Unknown Facility
Penticton, British Columbia, V2A 5C8, Canada
Unknown Facility
Saint John, New Brunswick, E2L 4L2, Canada
Unknown Facility
Burlington, Ontario, L7R 4C4, Canada
Unknown Facility
Kitchener, Ontario, N2G 1G3, Canada
Unknown Facility
Oakville, Ontario, L6J 3M5, Canada
Unknown Facility
Oshawa, Ontario, L1G 2B9, Canada
Unknown Facility
Ottawa, Ontario, K1Y 4E9, Canada
Unknown Facility
Peterborough, Ontario, K9J 7C6, Canada
Unknown Facility
Scarborough Village, Ontario, M1E 4B9, Canada
Unknown Facility
Windsor, Ontario, N9A 1E1, Canada
Unknown Facility
Beijing, 100035, China
Unknown Facility
Beijing, 100044, China
Unknown Facility
Beijing, 100853, China
Unknown Facility
Shanghai, 200025, China
Unknown Facility
Shanghai, 200032, China
Unknown Facility
Shanghai, 200233, China
Unknown Facility
Bogotá, Colombia
Unknown Facility
Cali, Colombia
Unknown Facility
Medellín, Colombia
Unknown Facility
Prague, Tschechien, 180 81, Czechia
Unknown Facility
Brno, 62500, Czechia
Unknown Facility
Chomutov, 430 01, Czechia
Unknown Facility
Havlíčkův Brod, 580 01, Czechia
Unknown Facility
Jihlava, 586 01, Czechia
Unknown Facility
Kolín, 280 00, Czechia
Unknown Facility
Pardubice, 530 03, Czechia
Unknown Facility
Pilsen, 304 60, Czechia
Unknown Facility
Frederiksberg, 2000, Denmark
Unknown Facility
Hellerup, 2900, Denmark
Unknown Facility
Herlev, 2730, Denmark
Unknown Facility
Hørsholm, DK-2970, Denmark
Unknown Facility
Silkeborg, 8600, Denmark
Unknown Facility
Bois-Guillaume, 76230, France
Unknown Facility
Clermont-Ferrand, 63050, France
Unknown Facility
Liévin, 62806, France
Unknown Facility
Marseille, 13008, France
Unknown Facility
Monaco, 98000, France
Unknown Facility
Nantes, 44277, France
Unknown Facility
Nice, 06000, France
Unknown Facility
Nice, 06002, France
Unknown Facility
Paris, 75019, France
Unknown Facility
Paris, 75674, France
Unknown Facility
Paris, 75877, France
Unknown Facility
Paris, 75960, France
Unknown Facility
Soyaux, 16800, France
Unknown Facility
Vandœuvre-lès-Nancy, 54511, France
Unknown Facility
Bad Mergentheim, Baden-Wurttemberg, 97980, Germany
Unknown Facility
Rheinfelden, Baden-Wurttemberg, 79618, Germany
Unknown Facility
Fürth, Bavaria, 90766, Germany
Unknown Facility
Garmisch-Partenkirchen, Bavaria, 82467, Germany
Unknown Facility
Würzburg, Bavaria, 97080, Germany
Unknown Facility
Sommerfeld, Brandenburg, 16766, Germany
Unknown Facility
Bremen, City state Bremen, 28205, Germany
Unknown Facility
Frankfurt am Main, Hesse, 60528, Germany
Unknown Facility
Frankfurt am Main, Hesse, 65929, Germany
Unknown Facility
Düsseldorf, North Rhine-Westphalia, 40225, Germany
Unknown Facility
Witten, North Rhine-Westphalia, 58448, Germany
Unknown Facility
Beersheba, Israel, 84101, Israel
Unknown Facility
Haifa, Israel, 31096, Israel
Unknown Facility
Holon, Israel, 58100, Israel
Unknown Facility
Kfar Saba, Israel, 44281, Israel
Unknown Facility
Tel Aviv, Israel, 64239, Israel
Unknown Facility
Ẕerifin, Israel, 70300, Israel
Unknown Facility
Tel Litwinsky, 52621, Israel
Unknown Facility
San Donato Milanese, Milano, 20097, Italy
Unknown Facility
Abano Terme, Padova, 35031, Italy
Unknown Facility
Gubbio, Perugia, 06024, Italy
Unknown Facility
Alghero, Sassari, 07041, Italy
Unknown Facility
Bologna, 40136, Italy
Unknown Facility
Florence, 50139, Italy
Unknown Facility
Lecco, 23900, Italy
Unknown Facility
Padua, 35127, Italy
Unknown Facility
Parma, 43100, Italy
Unknown Facility
Roma, 00168, Italy
Unknown Facility
Udine, 33100, Italy
Unknown Facility
Varese, 21100, Italy
Unknown Facility
Chihuahua, Chih., Chihuahua, 31000, Mexico
Unknown Facility
Guadalajara, Jalisco, 44280, Mexico
Unknown Facility
Hermosillo, Sonora, 83000, Mexico
Unknown Facility
Amsterdam, 1105 AZ, Netherlands
Unknown Facility
Hilversum, 1213 XZ, Netherlands
Unknown Facility
Hoofddorp, 2134 TM, Netherlands
Unknown Facility
Leiden, 2334 CK, Netherlands
Unknown Facility
Nijmegen, 6522 JV, Netherlands
Unknown Facility
Oss, 5342 BT, Netherlands
Unknown Facility
Zwolle, 8011 JW, Netherlands
Unknown Facility
Elverum, 2409, Norway
Unknown Facility
Gjøvik, 2819, Norway
Unknown Facility
Kongsvinger, 2212, Norway
Unknown Facility
Lillehammer, 2609, Norway
Unknown Facility
Namsos, 7800, Norway
Unknown Facility
Callao, CALLAO 2, Peru
Unknown Facility
Lima, LIMA 11, Peru
Unknown Facility
Lima, LIMA 1, Peru
Unknown Facility
Bialystok, 15-276, Poland
Unknown Facility
Bydgoszcz, 85-094, Poland
Unknown Facility
Gdansk, 80-803, Poland
Unknown Facility
Krakow, 31-826, Poland
Unknown Facility
Lodz, 91-002, Poland
Unknown Facility
Lublin, 20-090, Poland
Unknown Facility
Lublin, 20-718, Poland
Unknown Facility
Szczecin, 71-252, Poland
Unknown Facility
Warsaw, 00-909, Poland
Unknown Facility
Warsaw, 02-637, Poland
Unknown Facility
Bloemfontein, Freestate, 9300, South Africa
Unknown Facility
Johannesburg, Gauteng, 2132, South Africa
Unknown Facility
Pretoria, Gauteng, 0084, South Africa
Unknown Facility
Pretoria, Gauteng, PRETORIA, South Africa
Unknown Facility
Pretoria, Gauteng, South Africa
Unknown Facility
Randburg, Gauteng, 2125, South Africa
Unknown Facility
Durban, KwaZulu-Natal, 4030, South Africa
Unknown Facility
Newcastle, KwaZulu-Natal, 2940, South Africa
Unknown Facility
Somerset West, Western Cape, 7130, South Africa
Unknown Facility
Worcester, Western Cape, 6850, South Africa
Unknown Facility
Badalona, Barcelona, 08916, Spain
Unknown Facility
Barcelona, Barcelona, 08006, Spain
Unknown Facility
Barcelona, Barcelona, 08035, Spain
Unknown Facility
Barcelona, Barcelona, 08036, Spain
Unknown Facility
Castellon, Castellón de La Plana, 12004, Spain
Unknown Facility
Jaén, Jaén, 23007, Spain
Unknown Facility
Alcorcón, Madrid, 28922, Spain
Unknown Facility
Madrid, Madrid, 28040, Spain
Unknown Facility
Pamplona, Pamplona, 31008, Spain
Unknown Facility
Valencia, Valencia, 46010, Spain
Unknown Facility
Falköping, 521 85, Sweden
Unknown Facility
Gothenburg, 416 85, Sweden
Unknown Facility
Halmstad, 301 85, Sweden
Unknown Facility
Hässleholm, 281 25, Sweden
Unknown Facility
Jönköping, 551 85, Sweden
Unknown Facility
Kungälv, 442 83, Sweden
Unknown Facility
Lidköping, 531 85, Sweden
Unknown Facility
Varberg, 432 81, Sweden
Related Publications (1)
Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2776-86. doi: 10.1056/NEJMoa076016.
PMID: 18579812DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bayer Study Director
Bayer
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
August 8, 2006
First Posted
August 9, 2006
Study Start
February 1, 2006
Primary Completion
January 1, 2007
Study Completion
January 1, 2007
Last Updated
October 27, 2014
Record last verified: 2014-10